title: Expression of the Metastasis Suppressor KAI1 in Uveal Melanoma.
abstract: Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus in this field at present. KAI1 is a metastasis suppressor gene that has been reported to play a role in various human malignancies, although it has not previously been evaluated in UM. Purpose. To investigate the expression of KAI1 in UM and its potential value as a prognostic marker. Materials and Methods. 18 cases of human primary UM were collected and immunostained for KAI1 expression. A pathologist evaluated staining intensity and distribution semiquantitatively. Each case was categorized as group 1 (low staining) or group 2 (high staining). Results. In group 2, two of the 12 cases presented with metastasis. Conversely, in group 1, five out of 6 cases had metastasis. The mean follow-up of patients who did not develop metastasis was 81.81 months (median: 75 months) versus 42.14 months (median: 44 months) for patients with metastasis. Conclusions. KAI1 is a promising candidate marker that may offer prognostic value in UM; it may also represent a therapeutic target in metastatic disease.
authors: The Henry C. Witelson Ocular Pathology Laboratory, McGill University, 3775 University Street, Room 216, Montreal, QC, Canada H3A 2B4.
authors: Shawn C
authors: SC
authors: Maloney
authors: Bruno F
authors: BF
authors: Fernandes
authors: Rafaella Cleto
authors: RC
authors: Penteado
authors: Emilia
authors: E
authors: Antecka
authors: Vasco
authors: V
authors: Bravo-Filho
authors: Debra Meghan
authors: DM
authors: Sanft
authors: Miguel N
authors: MN
authors: Burnier
references: Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3943-53
references: 15217924
references: Int J Mol Med. 2004 Oct;14(4):517-27
references: 15375577
references: Am J Pathol. 2001 Nov;159(5):1629-34
references: 11696423
references: Nat Rev Cancer. 2003 Jan;3(1):55-63
references: 12509767
references: Am J Pathol. 1999 Jun;154(6):1665-71
references: 10362791
references: Cancer Lett. 1998 Jul 17;129(2):229-34
references: 9719466
references: Surv Ophthalmol. 1988 Jan-Feb;32(4):239-51
references: 3279559
references: Cancer J. 2012 Mar-Apr;18(2):148-52
references: 22453016
references: J Pathol. 2011 Jan;223(1):4-14
references: 20938929
references: Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
references: 14578381
references: Pigment Cell Melanoma Res. 2012 Mar;25(2):171-81
references: 22268848
references: Clin Cancer Res. 2000 Sep;6(9):3424-9
references: 10999724
references: APMIS. 2008 Jul-Aug;116(7-8):586-601
references: 18834404
references: Jpn J Cancer Res. 1998 Apr;89(4):397-404
references: 9617345
references: Cancer Treat Rev. 2012 Aug;38(5):549-53
references: 22270078
references: Cancer Lett. 2006 Aug 28;240(2):183-94
references: 16260083
references: FEBS Lett. 2011 Oct 20;585(20):3166-73
references: 21875585
references: J Exp Clin Cancer Res. 1998 Sep;17(3):307-11
references: 9894767
references: Cancer Res. 1996 Apr 15;56(8):1751-5
references: 8620488
references: J Clin Oncol. 2001 May 1;19(9):2422-32
references: 11331321
references: J Bioenerg Biomembr. 2006 Aug;38(3-4):151-61
references: 16944301